Presented by:
Daniel R. Seichepine, Ph.D.
About the Webinar:
Recent advances in blood-based biomarkers, genetic testing, and disease-modifying therapies are transforming how Alzheimer's disease is diagnosed and treated. These developments also raise important questions about the evolving role of clinical neuropsychologists.
This presentation will review emerging Alzheimer's disease biomarkers, the clinical significance of APOE genotype, and the benefits and limitations of anti-amyloid monoclonal antibody therapies. Particular emphasis will be placed on how neuropsychologists can contribute to early identification, differential diagnosis, and treatment eligibility decisions. Practical examples from clinical evaluations will illustrate how these advances can be integrated into neuropsychological practice.
Learning Objectives:
By the end of this presentation, participants will be able to:
-
Identify the clinical applications and limitations of emerging blood-based biomarkers for Alzheimer's disease.
-
Identify key benefits and risks of anti-amyloid monoclonal antibody therapies, including the role of APOE genotype in treatment-related risk assessment.
-
Identify ways neuropsychological assessment can contribute to the early diagnosis of Alzheimer's disease and multidisciplinary decisions regarding treatment eligibility.
About the speaker:
Daniel R. Seichepine, Ph.D., is an Associate Professor of Clinical Psychology at William James College and a clinical neuropsychologist practicing in Massachusetts and New Hampshire. He is also the owner of Next Step Neuropsychology, a private practice specializing in the evaluation of cognitive and neurological disorders.
Dr. Seichepine earned his Ph.D. from Boston University and completed his postdoctoral training at the Boston University Alzheimer's Disease Center. Before joining William James College, he spent 12 years on the faculty at the University of New Hampshire.
His clinical and research interests include Alzheimer's disease, cognitive aging, and traumatic brain injury. For more than a decade, he has served as a consultant on international clinical trials investigating treatments for Alzheimer's and Parkinson's diseases, including trials evaluating disease-modifying therapies for Alzheimer's disease. He regularly presents to professional and public audiences on advances in Alzheimer's disease diagnosis and treatment.
The Massachusetts Neuropsychological Society is approved by the American Psychological Association to sponsor continuing education for psychologists. The Massachusetts Neuropsychological Society maintains responsibility for this program and its content.